The complications and costs of chronic dialysis in 4 patients with renal failure due to multiple myeloma are presented. In three patients the paraprotein responded to chemotherapy though without recovery of renal function. These three patients are alive after 18, 16 and 15 months of dialysis, the other dying after 7 months. Hospital admissions ranged from 26 to 74 days per year with infections accounting for 54 to 87% of admission days, 62.5% of which occurred during the first three months of dialysis treatment, with an incidence of 2.4 to 6.9 admissions episodes per year.
Introduction
Several published series have demonstrated that patients with severe chronic renal failure secondary to multiple myeloma can be successfully dialysed.'-3 Such patients would otherwise have died of renal failure rather than myeloma. There is little published information on the complications encountered by the myeloma patients on chronic dialysis and hence the cost of offering such treatment.
Bacterial infections are a major cause of morbidity and mortality in myeloma patients,4 with azotaemia being suggested as a further independent risk factor to increase the infection risk.5 Patients suffering from myeloma are often elderly (> 55 years of age) and hence would be classed as high risk dialysis patients independent of the systemic disease from which they suffer.6 They would also be unsuitable for renal transplantation. Such restraints imply a more difficult and expensive treatment regime.
In the modern climate All patients presented with severe renal failure (serum creatinine > 295 gmol/l). In 3, dialysis was not deemed necessary from between 2 and 7 months from presentation when initial treatment was by haemodialysis, though one patient (number 4) was subsequently trained for continuous ambulatory peritoneal dialysis (CAPD), the remaining three being on a hospital maintenance haemodialysis programme.
Chemotherapy
All patients had intermittent chemotherapy dependent on blood count. The different regimes used were: patient 1 -intravenous vincristine, adriamycin and oral dexamethasone.'°Prophylactic co-trimoxazole one twice daily, ketoconazole 600 mg and cimetidine 400 mg twice daily, were given for 7 days with each course." Patient and 46 days/dialysis/year and 2.4 and 6.9 admission episodes/year (Table I) . Three of the patients also had minor infections treated on an out-patient basis, (Table III) . Ltd), the cannula being used for between one week (patient 4) to 6 months (patient 3).
Costing
The total cost of antibiotics ranged from £308.00 to £510.00 with an annual cost of £205.00 to £579.00 There was a wide range in the costing for each variable (Table II) . (Table III) The duration of hospital admission adds greatly to the annual cost. We do not suggest that only myeloma patients are at risk of such admissions, yet it seems a common pattern both from Leicester and our own experience, that myeloma patients on chronic dialysis, have more frequent and longer durations of hospitalization.
From our own experience and other published data, we conclude that long-term survival on dialysis is possible for myeloma patients and a good quality of life is achieved if a response to chemotherapy is obtained. Chronic dialysis in myeloma is 5-33% more expensive than routine dialysis and the extra cost is mostly due to the number and duration of hospital admissions for infection. The costs of chemotherapy, antibiotics and blood products are relatively small in comparison to the 'hotel costs' ofin-patient treatment.
